← Eichor
Study identifier: NCT06512194 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Investigation to Understand and Optimize Psilocybin

Condition: Depression  ·  Sponsor: Charles Raison

PhasePhase 2
Planned participants141
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore objective measures of real-world social behavior and identify early behavioral responses that may be associated with long-term treatment outcomes.

This description comes directly from the study's public registry record.

Talk to the study team

Program Manager  ·  (970) 855-7374  ·  bhic@vailhealth.org

Always discuss trial participation with your own doctor first.

Locations (1)

Vail Health Behavioral HealthEdwards, Colorado, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06512194